Viking Therapeutics
Stories
-
Viking Therapeutics registers Phase 3 trial of VK2735 for weight management
The study, titled SUNRISE 1, is a Phase 3 randomized, double-blind, placebo-controlled trial of VK2735 administered orally for weight management. It plans to enroll 560 participants starting October 15, 2026, with primary completion projected for July 2028.
-
Viking Therapeutics registers Phase 3 trial of VK2735 for weight management in type 2 diabetes
The study plans to enroll 560 participants and is expected to begin on October 16, 2026. It plans to evaluate oral VK2735 for weight management in adults with type 2 diabetes who are obese or overweight.